This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Global Transfection (Gene Delivery, DNA Delivery, Protein Delivery, SiRNA Delivery) Technologies Market Report 2012 - 2017

DUBLIN, April 12, 2013 /PRNewswire/ --

Research and Markets has announced the addition of the " Global Transfection (Gene Delivery, DNA Delivery, Protein Delivery, SiRNA Delivery) Technologies (Lipofection, Calcium Phosphate, Electroporation, Nucleofection, Magnetofection, Gene Gun, Viral) Market (2012 - 2017)" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Transfection is an enabler technology used for many cell based research activities with applications spanning production of recombinant proteins and recombinant cell lines, gene therapy, delivery of therapeutics and also drug discovery. This research report provides a brief description on transfection technologies, its evolution, comparative analysis, market landscape analysis, competitive scenario and emerging technology and application trends. Global research and development Network, Innovation and Spin offs have been discussed. The report tracks regional adoption and development trends, providing strategic recommendation to stay active and compete in the market space. An impact analysis of major drivers and restraints influencing the growth of the market is mapped for five year period. Key Driver: Advances in cell research and therapeutic delivery Cell research is a major driving factor for transfection market, as more than 60% of the users are of academic institutions and researchers. Research in gene transfer is being performed in in vivo conditions for different therapeutic applications; there is a growing demand for new transfection technologies to address unmet needs for therapeutic delivery which is driving the transfection market. Key Restraint: Home brew Reagents restricts sale of commercial kits Home brew reagents are still the preferred choice of reagents for transfection by researchers all over the world. Most of the researchers prepare their own reagents from their laboratory to conduct their research. This is true for most of the reagent based transfection reactions. This allows them to reduce cost involved in purchasing commercial kits. Key Challenge: New disruptive technologies required to address transfection in hard-to-transfect cells Transfection is an enabler technology which is used in many cell research activities, however only few cell lines are majorly used in these experiments restricting the scope of the study. Transfection in hard to transfect cells is the need of hour and it is a major challenge. There are few upcoming transfection technologies like nucleofection and magnetofection - which are an off-shoot of electroporation, which have the potential to address these challenges but are currently cost prohibitive due to which the technologies may have a much slower uptake in the developing world. Key Topics Covered: 1. Introduction 2. Executive Summary 3. Transfection Technologies - Technology Landscape Analysis 4. Transfection - Market Landscape Analysis 5. Global R&D Portfolio Analysis

6. Investment/Funding Analysis

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs